Demonstrating why it has a dominant position in clinical diagnostics, Abbott (NYSE:ABT) has launched its
third COVID-19 test, this time a blood test that detects IgG antibodies
to SARS-CoV-2 that is performed on automated instruments.
It expects to ship 1M tests this week and 4M in
April. It expects to supply enough product to screen as many as 20M
samples by June.
Its lab-based molecular test and its rapid point-of-care test, both detecting the virus itself, are already in use.
https://seekingalpha.com/news/3560863-abbott-launches-third-covidminus-19-test
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.